First-line combination therapy of immunotherapy plus anti-angiogenic drug for thoracic SMARCA4-deficient undifferentiated tumors in AIDS: a case report and review of the literature

• Published in: Frontiers in immunology Vol. 15; p. 1473578
• Main Authors: Wei, Xiaoling, Xing, Xiangju, Yao, Wei, Wang, Changzheng, Xiao, Yajie, Du, Xianzhi
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 09.01.2025
• Subjects: Acquired Immunodeficiency Syndrome - complications; Aged; aids; Angiogenesis Inhibitors - therapeutic use; anti-angiogenic drug; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; DNA Helicases - deficiency; DNA Helicases - genetics; Humans; Immunology; immunotherapy; Immunotherapy - methods; lung cancer; Lung Neoplasms - complications; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - pathology; Nuclear Proteins - deficiency; Nuclear Proteins - genetics; Thoracic Neoplasms - complications; Thoracic Neoplasms - drug therapy; Thoracic Neoplasms - genetics; Thoracic Neoplasms - pathology; thoracic SMARCA4-deficient undifferentiated tumor; Transcription Factors - deficiency; Transcription Factors - genetics; lung cancer; aids; anti-angiogenic drug; thoracic SMARCA4-deficient undifferentiated tumor; immunotherapy

Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UT) exhibit a notably aggressive phenotype, which is associated with poor patient survival outcomes. These tumors are generally resistant to conventional cytotoxic chemotherapy, thereby limiting the availability of effective treatment optio...